health-focused real world evidence
research projects that engage funding partners, decision makers, and knowledge users, as well as uphold academic standards that ensure integrity of results.
Medication use, health care resource utilization, and cost of adults living with MS in Alberta.
Care patterns among adults with newly diagnosed multiple sclerosis in Alberta.
The incremental health care cost of migraine in Alberta.
Post-stroke care pathways and spasticity treatment in Alberta.
Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population‑based cohort study.
Osman, M, Martins, K, Wong, KO, Vu, K, Guigue, A, Cohen Tervaert, JW, Gniadecki, R, Klarenbach, S. Scientific Reports. 2023;13:16444. doi: 10.1038/s41598-023-43880-7.
Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada.
Richer, L, Luu, H, Martins, K, Vu, K, Guigue, A, Wong, KO, Nguyen, PU, Rajapakse, T, Williamson, T, Klarenbach, S. Headache. 2023;63(9):1285-
Health care cost of severe obesity and obesity-related comorbidities: A retrospective cohort study from Alberta, Canada.
Butalia, S, Luu, H, Guigue, A, Martins, K, Williamson, T, Klarenbach, S. Obesity Research & Clinical Practice. 2023;Sep 12:S1871-403X(23)00109-6. doi: 10.1016/j.orcp.2023.09.006.
Analgesic Use Among Adults with a Trauma-Related Emergency Department Visit: A Retrospective Cohort Study from Alberta, Canada.
Sevcik, B, Lobay, K, Luu, H, Martins, K, Vu, K, Nguyen, PU, Bohlouli, S, Eurich, D, Lester, E, Williamson, T, Richer, L, Klarenbach, S. Pain and Therapy. 2023;12(4):1039-1053.
Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study.
Ritchie, B, Martins, K, Tran, D, Blain, H, Richer, L, Klarenbach, S. Allergy, Asthma & Clinical Immunology. 2022;18(1):99. doi: 10.1186/s13223-022-00735-6
Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study.
Wong, K, Klarenbach, S, Martins, K, Chue, P, Dursun, S, Snaterse, M, Guigue, A, So, H, Luu, H, Vu, K, Richer, L. BMC Psychiatry. 2022 Jul 2;22(1):444. do
Healthcare resource utilisation and disease-modifying therapy use over time among adults with newly diagnosed multiple sclerosis: a retrospective cohort study from Alberta.
Balcom, E, Smyth, P, McCombe, J, Kate, M, Vu, K, Martins, K, Aponte-Hao, S, Richer, L, and Klarenbach, S. The endMS Conference. 2023 Dec, Toronto, ON. Accepted.
Population based analysis of outcomes among persons with type 2 diabetes and chronic kidney disease.
Klarenbach, S, Collister, D, Bello, A, Wiebe, N, So, H, and Pannu, N. Canadian Society of Nephrology. 2022 May Montreal, PQ
Comparing Cortiment™ and prednisone in ulcerative colitis: a population-based study of outcomes.
Coward, S, Martins, K, Klarenbach, S, Kroeker, K, Ma, C, Panaccione, R, Richer, L, Seow, C, Targownik, L, and Kaplan, G. Journal of the Canadian Association of Gastroenterology. 2022 Mar; 5(Suppl 1):33-35. doi: 10.1093/jcag/
Health care resource utilization among patients with depression before and after initiating vortioxetine.
Chue, P, Martins, K, Wong, K, Ahmed, G, Klarenbach, S, and Richer, L. 34th ECNP Congress Hybrid, October 2021. CG21-0275
Opioid Use in Medical Cannabis Authorization Adult Patients from 2013-2018: Alberta, Canada.
Cerina L, Mu L, Martins K, Dyck J, Klarenbach S, Richer L, Jess E, Hanlon J, Hyshka E, and Eurich D. Canadian Public Health Association Conference. 2021 Oct
Real-world use of Cortiment™ in ulcerative colitis: a population-based study.
Coward, S, Martins, K, Klarenbach, S, Kroeker, K, Ma, C, Panaccione, R, Richer, L, Seow, C, Targownik, L, and Kaplan, G. Journal of the Canadian Association of Gastroenterology. 2021 Mar; 4(Suppl 1):161-162. doi: 10.1093/jcag/gwab002.153